Section 6: Education and Research 2019
DOI: 10.1136/ejhpharm-2019-eahpconf.606
|View full text |Cite
|
Sign up to set email alerts
|

6ER-009 Patient satisfaction and knowledge after switching from eviplera to odefsey

Abstract: DAL allowed immediate patient discharge in 73% of patients.The overall clinical success rate of DAL was 89%. Adverse events, mainly mild in intensity, were reported in six patients. The total cost of DAL was C ¼ 62 179. Overall, DAL was estimated to reduce hospitalisation by 273 days, with an estimated overall cost reduction of C ¼ 67 466 (C ¼ 3551 per patient). Conclusion DAL appears to be an effective and safe therapy in several serious gram-positive infections. Its use to facilitate hospital discharge can p… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles